Automation Workflow for Closed-Loop Design-Make-Test-Analyze (DMTA) Cycles

By automating the handoffs between design, synthesis, and testing, a custom DMTA workflow collapses cycle times from months to weeks. AI agents translate design ideas into synthesis instructions for robotic platforms, schedule assays, and ingest results without manual intervention. This continuous, high-throughput loop allows medicinal chemistry teams to explore more chemical series and converge on optimal leads faster, directly reducing time-to-candidate by 40-60%.

Automated orchestration maximizes the utilization of expensive robotic synthesis and high-throughput screening (HTS) assets. The workflow intelligently batches synthesis requests, optimizes assay plate design, and routes compounds based on predicted value, reducing reagent waste and idle instrument time. By front-loading in silico filters (ADMET, synthesizability) and automating low-value tasks, you redirect skilled chemist and biologist FTE towards high-value hypothesis testing, improving R&D operating leverage.

A closed-loop system enforces data standardization from the point of generation. Agents structure raw spectroscopic (NMR/MS) data, tag experimental metadata, and automatically populate ELNs and compound registries. This creates clean, machine-readable training data for predictive AI models (e.g., for binding affinity or PK). Continuous retraining workflows, triggered by new experimental results, ensure models stay accurate, reducing prediction drift and improving the reliability of in silico design recommendations.

Automated agents apply in silico toxicology and off-target profiling to every designed molecule before synthesis. This acts as an early gatekeeper, filtering out compounds with hERG or PAINS liabilities and flagging selectivity risks. By embedding safety and developability checks directly into the design-test loop, you prevent the costly pursuit of flawed chemical series, reducing late-stage attrition and building a pipeline with higher probability of technical and regulatory success.

Orchestration enables parallel, multi-parameter optimization across several lead series simultaneously. The system can manage dozens of concurrent design-make-test cycles, applying project-specific MPO (Multi-Parameter Optimization) scoring to rank candidates. This scalable architecture allows a single team to advance more projects or explore a wider design space within a project, directly increasing the number of viable preclinical candidates generated per year and improving portfolio optionality.

A governed workflow captures the full lineage of every decision—from initial design rationale to synthesis instructions and assay results. This creates an immutable audit trail for IP protection, regulatory submissions, and internal governance. Automated model monitoring and version control ensure all AI components are validated and performance-documented, providing the explainability and compliance framework required for GxP-aligned discovery work and building institutional knowledge.

This agent translates project goals (e.g., target profile, IP constraints) into novel molecular structures using conditioned generative models. It then validates novelty against patent corpora and runs retrosynthesis AI to propose feasible synthetic routes, scoring for complexity and reagent availability. It outputs structured synthesis instructions (e.g., RXN files) for the robotic synthesis platform.

A core system agent that translates digital synthesis plans into executable commands for robotic liquid handlers, reactors, and purification systems (e.g., Chemspeed, HighRes Biosolutions). It manages inventory checks, schedules runs, monitors reaction telemetry, and handles basic exceptions (e.g., low solvent). It ingests raw analytical data (LCMS, NMR) and passes it to the analysis layer.

This agent manages the physical testing pipeline. Upon compound registration, it schedules biochemical or cellular assays on appropriate robotic platforms, optimizing for plate density and reagent use. It automatically ingests raw assay results (e.g., luminescence, fluorescence data) from plate readers and LIMS, normalizes the data, and flags quality control failures for review.

The central analytical brain of the loop. This agent aggregates new experimental data (potency, selectivity, solubility) with predictive ADMET profiles. It applies project-specific MPO scoring algorithms, updates Structure-Activity Relationship (SAR) models, and visualizes the chemical series in multi-dimensional property space. Its output is a prioritized list of design ideas for the next cycle, targeting specific property improvements.

This orchestration layer (built on frameworks like LangGraph) defines the workflow state machine, manages handoffs between agents, and enforces business rules. It handles approval gates (e.g., chemist review of proposed designs), maintains a complete audit trail of all decisions and data, and monitors for model drift or system exceptions. It ensures the loop is reproducible, defensible, and aligned with project governance.

Not an agent, but the critical infrastructure. A cloud data lake (e.g., on AWS/Azure) with a unified schema that connects all components: a compound registry (CDD Vault, Dotmatics), ELN data, assay results, and model predictions. It provides a single source of truth for agents to query and update, ensuring data integrity and enabling continuous model retraining. Integration with legacy systems (e.g., SAP for reagents) is managed here.

Automates the translation of digital molecular designs into executable synthesis instructions for robotic platforms (e.g., Chemspeed, HighRes Biosolutions). An orchestration agent validates the proposed structure against internal compound registries, runs a retrosynthesis planning model to generate a route, checks digital inventory for available building blocks, and formats the procedure into a platform-specific worklist (JSON/XML). This eliminates manual protocol writing and scheduling, reducing the design-to-flask timeline from days to hours and maximizing robotic asset utilization.

Orchestrates the post-synthesis testing pipeline. Upon synthesis completion, a scheduling agent checks the biochemical or cellular assay calendar, allocates plate space on liquid handlers (e.g., Hamilton, Tecan), and triggers sample logistics. A separate data-ingestion agent monitors instrument output folders (e.g., from EnVision plate readers, LC-MS systems), parses raw data files, applies QC checks, and pushes structured results (IC50, AUC, purity) to a central assay database. This flow removes manual plate booking and error-prone data transcription, ensuring rapid, auditable turn-around from compound to activity data.

Closes the learning cycle by automatically updating AI models with new experimental results. A model governance agent monitors the assay database for new batch results, triggers a validation pipeline to assess if the new data causes predictive drift in property models (e.g., potency, ADMET). If drift is detected, it orchestrates a retraining job on secure cloud HPC, validates the new model version against a hold-out set, and deploys it to the production design environment. This creates a self-improving system where each cycle's data makes the next cycle's predictions more accurate.

Maintains a single source of truth by automatically synchronizing all experimental and design actions. Agents watch for events (e.g., synthesis job completed, assay result posted) and write structured, timestamped entries to the Electronic Lab Notebook (ELN) (e.g., Benchling, Dotmatics) and the project management database. This includes linking digital design IDs to physical batch IDs, attaching analytical spectra, and logging all predictive scores used for decision-making. This integration is critical for audit trails, reproducibility, and providing chemists with a complete, real-time view of their series' data.

Embeds controlled escalation points for project team review without breaking automation. Business rule agents monitor cycle outputs against predefined thresholds (e.g., potency >100nM, synthesizability score <5). Candidates meeting advancement criteria are routed to a digital review queue in a platform like Jira or a custom dashboard, triggering notifications to project leads. For critical failures (e.g., repeated synthesis errors), alerts are routed to lab operations. This ensures scientists steer the process while automation handles the routine execution and triage.

Manages the underlying cloud and HPC resources required for compute-intensive steps. A resource agent receives jobs from the design workflow (e.g., 500,000 molecular docking simulations) and dynamically provisions the required GPU/CPU clusters on AWS Batch, Google Cloud Life Sciences, or an on-premise Slurm cluster. It manages job queuing, monitors for failures, and optimizes for cost and speed. This abstraction allows scientists to launch massive virtual screens without managing infrastructure, turning fixed compute cost into variable, outcome-driven expense.